Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMNN 001

Next Previous
Drug Profile

IMNN 001

Alternative Names: DNA-based immunotherapy - Imunon; EGEN-001; GEN-1; IL-12 gene therapy - EGEN; IL-12 gene therapy - Expression Genetics; IL-12 gene therapy - Imunon; IMNN-001; Interleukin-12 gene therapy - EGEN; Interleukin-12 gene therapy - Expression Genetics; Interleukin-12 gene therapy - Imunon; phIL-12-005/PPC

Latest Information Update: 24 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Expression Genetics
  • Developer Gynecologic Oncology Group; Imunon
  • Class Antineoplastics; Cytokine genes; Gene therapies; Immunotherapies
  • Mechanism of Action Interleukin 12 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase II Fallopian tube cancer; Peritoneal cancer
  • No development reported Colorectal cancer
  • Discontinued Glioblastoma

Most Recent Events

  • 22 Sep 2025 Efficacy data from a phase III OVATION 3 trial in Ovarian cancer released by Imunon
  • 22 Sep 2025 Pharmacodynamics data from a phase I/II trial in Peritoneal cancer released by IMUNON
  • 03 Jun 2025 Efficacy data from a phase I/II OVATION 2 trial in Ovarian cancer released by Imunon

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top